Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Pluri Inc (PLUR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Pluri Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.140 +0.140    +2.80%
14:52:12 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 11,058
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.970 - 5.140
Pluri Inc 5.140 +0.140 +2.80%

PLUR Ratios

 
Assess the performance of Pluri Inc (PLUR). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Pluri Inc's latest financial reports. Compare the performance metrics of Pluri Inc (PLUR) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM -1.11 1.09
Price to Sales TTM 74.43 675.47
Price to Cash Flow MRQ -1.16 4.69
Price to Free Cash Flow TTM -1.41 -15.07
Price to Book MRQ 6.04 3.76
Price to Tangible Book MRQ 5.92 1.27
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 97.48% -4,897.48
Gross Margin 5YA 98.05% -1,082.94
Operating margin TTM -6,788.24% -9,285.36
Operating margin 5YA -55,366.87% -2,961.05
Pretax margin TTM -6,850.42% -8,799.37
Pretax margin 5YA -55,075.45% -2,026.09
Net Profit margin TTM -6,708.4% -8,793.59
Net Profit margin 5YA -55,075.45% -4,582.45
   
Revenue/Share TTM 0.07 38.38
Basic EPS ANN -6.18 7.48
Diluted EPS ANN -6.18 7.1
Book Value/Share MRQ 0.85 63.39
Tangible Book Value/Share MRQ 0.84 48.23
Cash/Share MRQ 1.06 17.73
Cash Flow/Share TTM -3.57 9.15
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM -173.61% -38.56
Return on Equity 5YA -131.34% -65.85
Return on Assets TTM -48.19% -13.67
Return on Assets 5YA -76.42% -11.41
Return on Investment TTM -46.05% -8.81
Return on Investment 5YA -86.58% -7.88
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 51.7% -26.07
EPS(TTM) vs TTM 1 Yr. Ago TTM 42.39% -69
5 Year EPS Growth 5YA 0% 5.33
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 5,150% 492.77
Sales (TTM) vs TTM 1 Yr. Ago TTM 10.53% 50.67
5 Year Sales Growth 5YA 41.83% 32.71
5 Year Capital Spending Growth 5YA -5.19% 21.68
   
Quick Ratio MRQ 6.76 5.98
Current Ratio MRQ 7.12 6.31
LT Debt to Equity MRQ 554.69% 39.18
Total Debt to Equity MRQ 692.38% -3.63
Efficiency    
Asset Turnover TTM 0.01 0.32
Inventory Turnover TTM - 5.92
Revenue/Employee TTM 2.90K 655.92K
Net Income/Employee TTM -198.83K -408.55K
Receivable Turnover TTM - 6.59
   
Dividend Yield ANN - 0.03
Dividend Yield 5 Year Avg. 5YA - 0.03
Dividend Growth Rate ANN 0% 0.81
Payout Ratio TTM - 1.86
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PLUR Comments

Write your thoughts about Pluri Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alon Oahyo
Alon Oahyo Aug 23, 2022 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
dangerous stockdont buy it
Alon Oahyo
Alon Oahyo Jan 31, 2022 1:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
anyone have recommendation on the stock?
Yossi Luzon
Yossi Luzon Jan 31, 2022 1:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yes, don't come near it
Yossi Luzon
Yossi Luzon Dec 22, 2021 2:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strongly to 0
joe bar
joe bar Apr 20, 2021 12:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well that will be something
Job Losm
Job Losm Dec 10, 2020 1:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will be 10$ back soon
Talala Rus
Talala Rus Dec 10, 2020 1:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not soon
Carlos Andres
Carlos Andres Nov 23, 2020 1:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good results??
Carlos Andres
Carlos Andres Nov 05, 2020 11:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to buy
Oil Boyle
Oil Boyle Jun 01, 2020 9:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Has Coronavirus treatment Patients on ventilators (high mortality rate) :  survival rate is 87.5% on the placenta cell therapy so far. 50m eur from EIB Phase 2 study ongoing (The study, a “randomized, double-blind, placebo-controlled, multicenter, parallel-group” trial, will treat 140 adult patients who are intubated and mechanically ventilated and are suffering from respiratory failure and ARDS due to COVID-19. The objective is to evaluate the efficacy and safety of one or two intramuscular (IM) injections, in three different dosages, of PLX-PAD for the treatment of ARDS resulting from COVID-19, the company said in the announcement.)
Shmuel Haramati
Shmuel Haramati May 21, 2020 8:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bh psti saved Ed Pierce, celeb from Broadway life, big deal!
Shmuel Haramati
Shmuel Haramati May 21, 2020 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.thedailybeast.com/how-edward-pierce-broadway-wicked-designer-fought-covid-19-and-made-medical-history
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email